Skip to main content

Table 4 Treatment options in different groups

From: Evaluation of treatment response in adults with relapsing MOG-Ab-associated disease

  Type I-IS
N = 61
aType II IS
N = 6
Type III IS
N = 8
bMS-DMD
N = 10
AZT
N = 19
MMF
N = 12
RTX
N = 30
Therapy choice, n (%)
 First line 15 (78.9) 6 (50) 19 (63.3) 5 (83.3)
(3 CYC, 1 MTX, 1 MiTX)
5 (62.5)
(3 CS, 2 IVIG)
10 (100)
(6 IFN, 1 TFN, 1 GA, 2 NTZ)
 Second line 3 (15.8) 5 (41.7) 5 (16.6) 1 (16.6)
(1 MTX)
3 (37.5)
(3 CS)
 Other lines 1 (5.3) 1 (8.3) 6 (29.4)  
 Patients discontinuing treatment, n (%) 9 (47.4) 7 (58.3) 3 (10) 6 (100) 5 (55.6) 7 (70)
Causes for discontinuing treatment, n (%)
 General intolerance 2 (22.2) 1 (14.3) 1 (33.3) 1 (14.3)
 Biological intolerance 2 (22.2) 1 (16.7)
 Physician decision 2 (22.2) 2 (28.6) 1 (33.3) 3 (50) 4 (80) 1 (14.3)
 Patient decision 1 (11.1)
 Treatment failure 2 (22.2) 4 (57.1) 1 (33.3) 2 (33.3) 1 (20) 4 (57.1)
 Pregnancy desire 1 (14.3)
  1. a One patient switched from CYC to MTX
  2. bThree patients switched from MS-DMD to another MS-DMD
  3. IS immunosuppressants, MS-DMD multiple sclerosis disease-modifying drugs, AZT azathioprine, MMF mycophenolate mophetile, RTX rituximab, CS corticoids, CYC cyclophosphamide, IVIG intravenous immunoglobulins, MTX methotrexate, MiTX mitoxantrone, IFN interferon, TNF teriflunomide, GA glatiramer acetate, NTZ natalizumab